We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
Sonic reaffirms earnings guidance and says it is on the hunt for “sensible” acquisitions Boards fac...
Read ArticleASX rises, but MinRes drops over transparency issues Fed boss Powell’s cautious rate cut stance coo...
Read ArticleASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results...
Read ArticleAussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors ret...
Read ArticleHighlights Tech stocks drive markets higher, with notable movements from Apple and Nvidia. Euro...
Read ArticleControl Bionics says it has overcome the “challenges” of the 2023-24 year Ord Minnett identifies th...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleASX down as RBA holds rates steady again Element 25 lands US$166m grant talks Supermarket stocks d...
Read ArticleASX up on Thursday, tech stocks rise boosted by NextDC Wodside Energy drops due to downgrade and o...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleThe ASX200 closed fairly flat at 8,103 points. Tomorrow sees the release of crucial Q2 growth num...
Read ArticleToday’s Closing Bell is brought to you by WeBull Securities ASX dipped as Woolworths and mining...
Read ArticleNoxopharm says two novel drug candidates significantly reduced glioblastoma (brain cancer) cell gro...
Read ArticleNoxopharm (ASX: NOX) has made ‘substantial progress’ with its Chroma technology platform, reporting...
Read ArticleGolden Deeps (ASX:GED) has announced that thick copper and zinc sulphide mineralisation has been i...
Read ArticleGood morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highligh...
Read ArticleThe ASX is likely to open steady as Wall Street was closed Iron ore prices have fallen but remain s...
Read ArticleASX ended 10-day winning streak ANZ, Tabcorp dropped after facing regulators Despite a crude price...
Read ArticleControl Bionics to gain US$4,300 reimbursement for its NeuroNode device Noxopharm begins a trial fo...
Read ArticleBiotech company Noxopharm Ltd (ASX:NOX) has announced that the first human trial testing SOF-SKN – a...
Read ArticleThis week’s Bulls N’ Bears Runner of the Week is … LiveHire. Its shares rallied 95.83 per cent on an...
Read ArticleASX gained on Wall Street boost and local earnings results CBA, AGL Energy, and Evolution Mining po...
Read ArticleAustralian biotech company Noxopharm (ASX: NOX) has announced encouraging new data regarding the dev...
Read ArticleNoxopharm’s CRO-67 shows significant tumour reduction The drug effectively targets both cancer and...
Read ArticleShares in Noxopharm (ASX:NOX) jumped nearly 40% in morning trades on Wednesday according to Cboe liv...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleS&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biot...
Read ArticleNoxopharm said joining the global alliance means it will connect with other organisations, i...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticleNoxopharm (ASX:NOX) is scaling up the production of its preclinical SOF-SKN lupus medication...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleNoxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for fu...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleLocal markets started slow before ripping into an all-time intraday high 10 of 11 sectors high...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleLocal markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but...
Read ArticleThe ASX benchmark has closed slightly higher on Monday Energy Sector gains after oil prices rose ov...
Read ArticleASX set to fall despite a modest rally on Wall Street Microchip stocks fell as Microsoft unveiled i...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleASX200 closes 0.9pc higher Property stocks and IT sector enjoy huge day Small caps led by DCL Th...
Read ArticleThe S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% f...
Read ArticlemRNA is set to be the new frontier in vaccines, but has serious side effects including inflammation...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleThe Australian sharemarket increased in value on Wednesday, as China's gross domestic product (GDP)...
Read ArticleDon't miss Friday's webinar discussing imaging tech, laser tech and agricultural REITs. Click here...
Read Article18 Oct 2023 - A snapshot of the stocks on the move, featuring Whitehaven Coal (ASX:WHC), Paradigm Bi...
Read ArticleAsk any chief of a development-stage biotech about the prospect of a partnering or licencing deal an...
Read ArticleBenchmark ASX index finishes +1% higher ASX Sectors led by Utilities (+4.2%) and all ended higher...
Read ArticleThis week’s Bulls N’ Bears top ASX runner is… Noxopharm. It skyrocketed 323 per cent to join other i...
Read ArticleBenchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Di...
Read ArticleBenchmark index finds some rare greenage, up 0.5% Property and IT Sectors lead broad-based gains,...
Read ArticleThe ASX200 is now at its lowest level in eleven months, closing down .8 of a per cent this afternoon...
Read ArticleIt's been another depressing session for the...
Read ArticleBenchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleFear continued to grip Wall Street last night, sending all of the United States' major indices back...
Read ArticleIt has been yet another difficult day for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade,...
Read ArticleAustralian biotechnology company Noxopharm (ASX: NOX) has been granted orphan drug designation (ODD)...
Read Article04 Oct 2023 - A snapshot of the stocks on the move, featuring Noxopharm (ASX:NOX), Redstone Resource...
Read ArticleNoxopharm (ASX:NOX) announces that the US FDA has granted Orphan Drug Designation (ODD) status to...
Read ArticleNew Zealand's central bank is likely to maintain its current interest rates ahead of a general elect...
Read ArticleASX to open lower, as markets fall in New York US 10-year yields continue to threaten 5%, so every...
Read ArticleThe US FDA has granted Orphan Drug Designation status to Noxopharm's (ASX:NOX) CRO-67 precli...
Read ArticleIt has been a stunning start to the day for ASX healthcare stock Noxopharm Ltd (ASX: NOX). In morni...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleASX200 drops sharply on Wall Street worry Healthcare only sector to rise Small caps led by Noxoph...
Read ArticleAnatara to progress in Phase 1/2 clinical trial of bowel syndrome Noxopharm to present data at conf...
Read ArticleFutures are tipping the ASX to open down this morning, following a mixed session of Wall Street and...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleAccording to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleThe ASX 200 has had its worst day in roughly a month with a 1.29 percentage dip The sectors were a...
Read ArticleASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market a...
Read ArticleBrisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “gam...
Read ArticleSmall cap health stocks are not known to pay dividends But there’s a handful of such stocks on the...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleNoxopharm (NOX) publishes preliminary data from its IONIC investigator-initiated pilot trial for its...
Read ArticleImmutep gets US FDA clearance to start Phase 1 study Noxopharm says its Sofra platform is effective...
Read ArticleThe ASX is expected to open slightly higher on Friday as reports suggest the US debt ceiling talks c...
Read ArticleThe ASX is set to open higher on Friday after a Wall Street rally overnight FAANG stocks lifted, wh...
Read ArticleThe ASX 200 benchmark has posted a solid slab of gains, up 0.78% for the day Energy and Materials h...
Read ArticleThe S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chi...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleHealth care stocks have surged in early trade, up more than a per cent. Biotech company Immuron m...
Read ArticleNoxopharm plunged 45pc after scaling down its Veyonda program Rhythm Biosciences rose 25pc after sa...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleNoxopharm (NOX) prioritises the development of its two “cutting-edge” preclinical technology platfor...
Read ArticleThe ASX is expected to slip on Thursday as eyes are once again on the Reserve Bank. The RBA is ex...
Read ArticleThe ASX jumped 0.3% after lunch as the RBA finally kept rates on hold. XGD All Ordinaries Gold soar...
Read ArticleNoxopharm has developed a new product candidate based on mRNA technology IDT nabs TGA licence exten...
Read ArticleNoxopharm (NOX) is developing a new mRNA “vaccine enhancer” product to improve the effectiveness of...
Read ArticleNoxopharm (ASX:NOX) has announced the development of a new product candidate based on mRNA t...
Read ArticleThe ASX is expected to open higher on Tuesday after the mood surrounding the ongoing banking turmoil...
Read ArticleThe ASX is poised to open higher on Tuesday US energy and bank stocks led Wall Street overnight Bin...
Read ArticleThe ASX climbed 0.4% today after investors threatened it with a stick Mt Monger (ASX:MTM) wins the...
Read ArticleNoxopharm (ASX:NOX) has announced that research from its inflammation-related Sofra preclini...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleNoxopharm (NOX) is set to progress to part two of its clinical trial of drug candidate Veyonda to tr...
Read ArticleThe ASX is set to end its four-day winning streak today The World Economic Forum began overnight Bi...
Read ArticleThe ASX is poised to fall sharply on Friday following a plunge on Wall Street Nasdaq fell by more t...
Read ArticleAustralian company Noxopharm (ASX:NOX) has provided an update on the IONIC Investigator-init...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleNoxopharm (NOX) receives a $5.01 million rebate under the Australian Government’s Research and Devel...
Read ArticleAvita Medical successfully achieved two co-primary endpoints Noxopharm received $5.011 million in R...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleNoxopharm (ASX:NOX) has announced the resignation of founder Dr Graham Kelly as a non-execut...
Read ArticleWall Street slump leads the ASX into an early morning drop. Thanks, Obama Benchmark strides deeper...
Read ArticleNoxopharm (ASX:NOX) has announced what it describes as encouraging new preclinical data from...
Read ArticleBiotron commences human trial of COVID-19 Pancreatic trial news from Noxopharm and Clarity Pharma V...
Read ArticleLocal shares will open much lower on Wednesday after a big plunge on Wall Street US CPI came in hig...
Read ArticleNoxopharm (NOX) reports “encouraging” new preclinical data from a dual-cell therapy pancreatic cance...
Read ArticleASX 200 sinks 2% Small caps get crushed, down 2.5% Region, AUD and miners sink on weaker China act...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleNoxopharm (ASX:NOX) has announced the addition of three US sites for its CEP-2 sarcoma study...
Read ArticleThe Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Me...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleASX Emerging Companies (XEC) index has closed 1.5% on Tuesday Index now over 10% the better since F...
Read ArticleNoxopharm’s (NOX) lead oncology drug Veyonda has been granted Orphan Drug Designation (ODD) by the...
Read ArticleAn ASX healthcare share is racing into the green today following an update from the US Food and Dru...
Read ArticleHighlights The ASX Small Ordinaries index was seen 0.49% up at 3,293.2, by 12:30 PM AEDT. RAP,...
Read ArticleNoxopharm (ASX:NOX) has announced that its lead oncology drug candidate Veyonda has been gra...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleASX to rise, but Wall Street falters on J Powell commments US stocks fell slightly overnight as US F...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleThe study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug...
Read ArticleThe company has a substantial arsenal of products and is channelling more funds into R&D to adva...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleThe clinical-stage drug development company is in a strong financial position following a recent R&a...
Read ArticleThe ASX has recovered following yesterday’s strong blow, closing up 1.29% with all 11 sectors finish...
Read ArticleNoxopharm (NOX) receives a $5.8 million cash refund under the Federal Government’s Research and Dev...
Read ArticleThe cash injection adds to Noxopharm’s robust cash position, which stood at A$23.6 million as of Sep...
Read ArticleThe ASX is down -0.3% today with the information technology sector taking the cake for the biggest d...
Read ArticleThe ASX 200 Health Index (XHJ) is falling by 1.5% at the time of writing, compared to the broader in...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price has leapt 6% this morning after announcing a change in exe...
Read Article“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited t...
Read ArticleNoxopharm Limited (NOX) announces a shift in leadership in preparation for an upcoming ‘growth phas...
Read ArticleDow Jones hits fresh highs US stocks finished in mixed territories overnight. The Dow index rose 0.5...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price is on the rise today after a clinical trial update. Noxoph...
Read ArticleThe ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the br...
Read Article"This phase two study builds on our phase one trial, where we saw promising signals that it may be p...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleNoxopharm (NOX) signs licensing agreement with Hudson Institute of Medical Research for its cutting...
Read ArticleAmplia targets human trials for pancreatic cancer drug Noxopharm subsidiary enters licence agreemen...
Read ArticleRNA drugs already under development by Hudson will add to existing Pharmorage assets and help positi...
Read ArticleThe hot debut of Evolution Energy Minerals (ASX:EV1) was not enough to save the ASX resources sector...
Read ArticleThe ASX posted steady gains to start the week on Monday, with investors preferences leaning towards...
Read Article“This grant not only provides substantial non-dilutive funding to Noxopharm, but it also lends exter...
Read ArticleAustralian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that it...
Read ArticleThe company believes that DARRT-treatment has the potential to revolutionise cancer treatment by red...
Read ArticleNoxopharm (ASX:NOX) has received Notices of Allowance from patent offices in Australia and E...
Read Article“If we can improve the performance of ICIs by the addition of Veyonda, it could make a massive impac...
Read ArticleWall Street gains as Tesla breaks US$1 trillion market cap US stocks rose overnight, led by a surge...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price is edging higher this afternoon and is currently trading u...
Read ArticleNoxopharm (NOX) is granted Australian and European patents for its use of Veyonda to achieve safer...
Read Article"A high proportion of cancer patients are deprived of the benefits of chemotherapies because of toxi...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index...
Read ArticleThe company is building a pipeline of drugs based on a unique and proprietary technology platform fo...
Read ArticleAustralian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that th...
Read Article“We see the allowance of this patent application as a major win for the company in our goal of seein...
Read ArticleThe clinical-stage drug development company focused on the treatment of cancer and cytokine release...
Read ArticleShares in drug company Noxopharm (ASX:NOX) climbed by around 4% this morning following the release o...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleThe discovery of idronoxil's anti-inflammatory mechanism adds a high-profile and potentially high-va...
Read ArticleIts partnership with Hudson Institute of Medical Research, NOX has also led to an important discover...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price has been a strong performer on Monday. The clinical-stage...
Read ArticleIDT Australia (ASX:IDT) jumped more than 20% after announcing that it has formalised activities with...
Read ArticleAnother red day for the ASX to close out the week. The ASX 200 closed 0.05% down from yesterday at 7...
Read ArticleThe broader ASX continued its losing streak, shedding another 0.5% while the benchmark ASX 200 close...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleThe clinical-stage drug development company’s collaboration with the US National Cancer Institute wi...
Read ArticleClinical-stage drug development company Noxopharm (ASX:NOX) has announced a formal collabora...
Read ArticleThe clinical-stage drug development company will team up with an arm of the National Institutes of H...
Read ArticleWall Street mixed despite blowout jobs numbers US stock market were mixed on Friday, despite stronge...
Read ArticleThe S&P/ASX200 closed up Thursday, gaining 7.90 points or 0.11% to 7,511.10 and setting a new 10...
Read ArticleIt now sees Veyonda having a major commercial future in the rapidly growing field of radioligand the...
Read ArticleASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which ro...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleIRIS Metals is set to become the latest Kookynie entrant to join the ASX boards, with its sights set...
Read ArticleNoxopharm is studying its Veyonda® drug candidate across a wide range of medical disciplines, with a...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleIt has an exciting pipeline of drugs under development and believes its novel technology platform is...
Read ArticleWith a key regulatory approval in place, Noxopharm is a step closer to starting a multi-national tri...
Read ArticleAustralian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that th...
Read ArticleThe clinical-stage drug development company believes, if a patent is granted, it will support its am...
Read ArticleShares in Noxopharm Ltd (ASX: NOX) are gaining today following the company’s announcement of a noti...
Read ArticleThe Phase Two trial will broaden the scope of studies into a potential cancer treatment using a high...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price is falling this afternoon. This comes after the company re...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleThe company is more than one drug – the business is a drug pipeline based on a novel technology plat...
Read ArticleSummary The S&P/ASX200 is trading 5.20 points higher to 7265.30 by the afternoon. The index...
Read ArticleNoxopharm welcomes this outcome given its recent LuPIN trial data showing even stronger survival out...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price is on course to end the week on a positive note. In morning...
Read ArticleSummary The ASX 200 closed lower by 19 points or 0.27% at 7142.60. The Australian dollar and bo...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price went gangbusters today after the company released a new re...
Read ArticleShareCafeAustralia…1 hour in… ASX200 up 3 ASX200 up 3 points to 7182. A2Milk (-0.5%); said it is...
Read ArticleWall Street higher as Biden proposed US$6 trillion budget All major indices rose on Friday, as US Pr...
Read ArticleIt was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies relea...
Read ArticleShareCafeNoxopharm (ASX: NOX) – Webinar Presentation Presenter – Graham Kelly – CEO & MD – Noxo...
Read ArticleShareCafeHidden Gems Webinar Recap – LAU, NOX, TZL, ANP, VMS Catch up on the full webinar with pres...
Read ArticleIn Part 1 of the study, an 1800 milligram dose of Veyonda® was determined to be well tolerated in pa...
Read ArticleSummary The WCN share price has closed up by 17.6%, as the company announced assay results. Qui...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at th...
Read ArticleThe ASX 200 has rebounded from yesterday’s loss though the technology sector has weighed on the mark...
Read ArticleNoxopharm Ltd (ASX: NOX) shares are having a bumper end to the week after the company released a ma...
Read ArticleCEP-2 will build on the encouraging outcomes of the CEP-1 pilot study where the chemo-enhancing effe...
Read ArticleDow Jones and iron ore reset records The Dow Jones index rose again overnight by 0.93%, resetting th...
Read ArticleThe aim of the CEP-1 study is to show that Veyonda boosts the effectiveness of conventional chemothe...
Read ArticleSummary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients...
Read ArticleThe data supports the international patent application lodged on 30 March 2021, making the provision...
Read ArticleThe data supports the international patent application lodged on 30 March 2021, making the provision...
Read ArticleNoxopharm (ASX:NOX) has provided interim data from its NOXCOVID trial that is assessing the...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price has started the week on a positive note. At the time of wr...
Read ArticleAustralian clinical-stage drug development company Noxopharm (ASX:NOX) has announced the lod...
Read ArticlePeter Switzer speaks to Graham Kelly, the founder, CEO and managing director of Noxopharm (NOX).
Read ArticleA phase 1b clinical trial testing the safety and efficacy of Noxopharm (ASX:NOX)‘s Veyonda supposito...
Read ArticleShareCafeAustralia…One Hour In…ASX200 down 69 points ASX200 down 69 points (1%) to 6676. Afterpay...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleDespite the healthcare leading the gains in the S&P/ASX 200 Index (ASX: XJO) yesterday, there a...
Read ArticleAustralian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that it...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price is raced higher on the open this morning. However, the Nox...
Read Article08 Mar 2021 - Drug development company Noxopharm (ASX:NOX) reports Veyonda has been approved to move...
Read ArticleShareCafeAustralia…One Hour In…ASX200 up 49 points ASX200 up 49 points (0.7%) to 6838. Don’t forge...
Read ArticleA trial of Noxopharm's (ASX: NOX) prostate cancer treatment has delivered a "high response" in men w...
Read ArticleShareCafeNoxopharm Study Finds its Drug Improves Prostate Cancer Survival Rates Noxopharm (ASX:...
Read ArticleAt time of writing, the share price of Noxopharm Ltd [ASX:NOX] is up more than 8%, trading at 74 cen...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price gained more than 21% today, surging in a last-minute buyin...
Read ArticleNoxopharm (ASX:NOX) has announced the publication in an abstract form of the latest survival...
Read ArticleShareCafeHidden Gems Webinar Recap – NOX, VMS, EMU, RXL Catch up on the full webinar with presentat...
Read ArticleShareCafeNoxopharm (ASX:NOX) – Hidden Gems Webinar Presentation Presenter – Dr. Graham Kelly Fo...
Read ArticleThe Noxopharm Ltd (ASX:NOX) share price launched up more than 7% today as the company released its...
Read ArticleNoxopharm (ASX:NOX) has announced that the latest formal review by the NOXCOVID-1 Safety Ste...
Read ArticleA trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final sta...
Read ArticleA trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final sta...
Read ArticleA trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final sta...
Read Article13 Jan 2021 - Drug development company, Noxopharm (ASX:NOX) reports that the latest formal review by...
Read ArticleNoxopharm CEO Dr Graham Kelly speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.
Read ArticleWhile the S&P/ASX 200 Index (ASX: XJO) is slipping today, the Australian clinical-stage drug de...
Read ArticleShareCafeAustralia…One Hour In…ASX up 52 points ASX200 up 52 points (0.8%) to 6685. Afterpay (+1....
Read ArticleAustralian clinical-stage drug development company Noxopharm (ASX:NOX) has completed a $23 m...
Read ArticleASX-listed drug developer is Noxopharm has put a $20 million equity raising to investors in an effor...
Read ArticleAustralian drug development company Noxopharm Limited (ASX: NOX) has announced a major breakthrough...
Read ArticleNoxopharm (ASX:NOX) has announced its investigative cancer therapy Veyonda will be trialed w...
Read ArticleThe Noxopharm Ltd (ASX: NOX) share price has started the week in a positive fashion. At one stage t...
Read Article05 Nov 2020 - Clinical-stage drug development company Noxopharm Limited (ASX:NOX) has partnered with...
Read ArticleBurgeoning medtech company Noxopharm (ASX: NOX) is making strides in the effort race to find a treat...
Read ArticleAustralian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that th...
Read ArticleAustralian biotech, Noxopharm Limited (ASX:NOX) has announced an important milestone with formal app...
Read ArticleClinical-stage drug development player, Noxopharm Limited (ASX:NOX) has recently announced peer-revi...
Read ArticleNew important pre-clinical data from two independent laboratories has validated the potential of Nox...
Read ArticleNew important pre-clinical data from two independent laboratories has validated the potential of Nox...
Read ArticleThe Noxofarm Ltd (ASX: NOX) share price soared after positive results regarding its cancer treatmen...
Read ArticleNoxopharm Limited (ASX:NOX) is trading ~5 per cent higher (as at 12:01 PM AEST) following the releas...
Read ArticleNyrada (ASX: NYR) has received “encouraging” results from a lab-based cholesterol-lowering study, fo...
Read ArticleNoxopharm (ASX:NOX) has announced the commencement of its NOXCOVID clinical program with a p...
Read ArticleAustralian clinical stage drug developer, Noxopharm Limited (ASX:NOX) notified in its latest update...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleSummary Noxopharm presented two sets of clinical data concerning the development of Veyonda® as a...
Read ArticleNoxopharm (ASX: NOX) has updated on its presentation of two sets of clinical trial data rela...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small ca...
Read ArticleCOVID-19 vaccines are driving markets but treatments are where most people believe a solution to the...
Read ArticleMarking a step forward, clinical-stage drug development company Noxopharm (ASX:NOX) has lodged a pre...
Read ArticleNoxopharm (ASX:NOX) has lodged a pre-Investigational New Drug (pre-IND) submission with the...
Read ArticleShares in Noxopharm Ltd (ASX:NOX) traded more than 40% higher on Tuesday afternoon after the company...
Read ArticleNoxopharm (ASX:NOX) has announced a $7.9 million capital raise its says will go towards prog...
Read ArticleOur summary of Noxopharm Ltd's recent announcement What's happened? Noxopharm Limited (ASX:NOX) anno...
Read ArticleWant to know which stocks the fund managers have been putting their money in (and out) of? We’ve kee...
Read ArticleBiotech company Noxopharm Limited (ASX:NOX) possesses an exciting new potential treatment for end-st...
Read ArticleIn a new development, clinical-stage oncology drug development player Noxopharm Limited (ASX:NOX) ha...
Read ArticleNoxopharm (ASX:NOX) has released details of the radiographic review of its DARRT-1 clinical...
Read ArticleOur summary of Noxopharm Ltd's recent announcement What's happened? Noxopharm Limited (ASX:NOX) toda...
Read ArticleClinical-stage Australian oncology drug development player Noxopharm (ASX:NOX) has revealed that the...
Read ArticleBiotech company Noxopharm (ASX: NOX) will seek approval from the US Food and Drug Administration for...
Read ArticleNoxopharm (ASX:NOX) is the latest biotech to announce it will test its drug against COVID-19. So how...
Read ArticleNoxopharm (NOX:ASX) has announced the active ingredient of its investigational therapy Veyon...
Read ArticleAustralian oncology drug development company Noxopharm (ASX:NOX), along with the Hudson Institute of...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleNoxopharm (ASX: NOX) is the latest small cap to reveal it has a potential COVID-19 treatment, after...
Read ArticleAustralian clinical stage drug development company Noxopharm Limited (ASX:NOX) recently announced a...
Read ArticleNoxopharm (ASX:NOX) has announced that the last patient has been enrolled and safely dosed i...
Read ArticleCEO Graham Kelly PhD said, “Bringing Veyonda to market for late-stage prostate cancer remain...
Read ArticleMirroring the wider market, many of the small cap IPOs completed so far in 2020 have white-knuckled...
Read ArticleLatest LuPIN Trial Interim Results and an Alliance with Oncology Services Provider, GenesisCare Furt...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleNoxopharm (ASX:NOX) has announced a new clinical alliance with oncology services provider Ge...
Read ArticleNyrada was established in 2017 to advance the non-oncology assets developed by Noxopharm, leaving No...
Read ArticleSydney biotech company Nyrada has made its debut on the ASX in the first float of the year following...
Read ArticleIt was a solid debut for drug manufacturer Nyrada (ASX:NYR) on the ASX this morning. Nyrada raised $...
Read ArticleFollowing an oversubscribed IPO, Noxopharm’s (NOX) U.S. spin-off Nyrada has listed on the ASX under...
Read ArticleAustralian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc experienced strong demand in its in...
Read Article20 Dec 2019 - Clinical drug development company Noxopharm (ASX:NOX) has released DARRT-1 study clini...
Read ArticleThe Boards of Noxopharm (NOX) and Nyrada have received full commitments for the $8.5 million IPO...
Read ArticleAntisense Therapeutics (ASX:ANP) jumped over 20 per cent this morning on news its ATL1102 drug, figh...
Read ArticleAustralian drug development company, Noxopharm Limited (ASX: NOX) recently announced the completion...
Read ArticleNoxopharm Ltd (ASX: NOX), a clinical-stage Australian drug development company, has secured an incre...
Read ArticleAustralian company Noxopharm (ASX:NOX) has reported positive end-of-study data from its DARR...
Read ArticleBiotech drug developer Noxopharm (ASX: NOX) has reported positive end-of-study results from its DARR...
Read ArticleAustralia headquartered clinical stage drug development company, Noxopharm Limited (ASX: NOX) has be...
Read ArticleEmerging Australian oncology company Noxopharm (ASX:NOX) has used its annual general meeting...
Read ArticleClinical-stage drug development company, Noxopharm Limited (ASX: NOX) continues to show its potenti...
Read ArticleThe company said Mr Hunter’s skills will add important management strength to its executive...
Read ArticleNoxopharm Limited (ASX: NOX) has recently provided an update related to the research progress on its...
Read ArticleThe TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opp...
Read ArticleSydney-based Noxopharm (ASX:NOX) has updated on interim data from the DARRT-1 study where Ve...
Read ArticleDrug development company Noxopharm (ASX: NOX) is growing more optimistic about the use of its Veyond...
Read ArticleAnti-cancer drug developer Noxopharm (ASX: NOX) has set the stage to present its highly-anticipated...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read Article16 Oct 2019 - Noxopharm (ASX:NOX) has made some changes to its senior executive and Board structures...
Read ArticleAustralian clinical-stage drug development company, Noxopharm Limited (ASX: NOX), has provided comme...
Read ArticleNoxopharm (ASX:NOX) has provided further information on the upcoming release of clinical dat...
Read ArticleNoxopharm (ASX: NOX) is in the process of making Veyonda®, which is a drug that boost the effectiven...
Read ArticleNoxopharm (ASX:NOX) has announced that scientific abstracts on interim data relating to its...
Read ArticleNoxopharm Limited is a clinical stage drug development company that is currently investing its lead...
Read ArticleNoxopharm (ASX:NOX) has provided an update on results from a series of proof-of-principle ex...
Read ArticleNoxopharm Limited (ASX: NOX) has recently released its quarterly report for the three months ended 3...
Read ArticleSydney-based company Noxopharm is developing a new approach to cancer treatment that is desi...
Read ArticleNoxopharm Limited (ASX: NOX) plans to accelerate the development of Veyonda® on the foundation of it...
Read ArticleMedibio (ASX: MEB) has gained 24 per cent this morning after announcing an integration partnership w...
Read ArticleNoxopharm Limited (ASX: NOX) is a clinical stage drug development company based in Australia. The co...
Read ArticleNoxopharm Limited (ASX: NOX) has released July 2019 edition of its Newsletter called ‘Versatility’....
Read ArticleClinical stage drug development company, Noxopharm Limited (ASX: NOX) aims to bring hope to cancer p...
Read ArticleIn the world of cancer, one billion-dollar molecule that has been making a big noise for its potenti...
Read ArticleThe big noise internationally in the treatment of prostate cancer is an experimental drug called 177...
Read ArticleClinical-stage drug development company, Noxopharm Limited (ASX: NOX) has released its updated corpo...
Read Article07 Jun 2019 - Noxopharm (ASX:NOX) has seen its majority-owned US subsidiary company, Nyrada receive...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
